Esperion Therapeutics Inc...

0.95
-0.01 (-1.44%)
At close: Apr 17, 2025, 3:59 PM
0.96
1.02%
After-hours: Apr 17, 2025, 07:56 PM EDT
-1.44%
Bid 0.95
Market Cap 187.48M
Revenue (ttm) 332.31M
Net Income (ttm) -51.74M
EPS (ttm) -0.28
PE Ratio (ttm) -3.38
Forward PE -4.74
Analyst Buy
Ask 0.96
Volume 4,199,074
Avg. Volume (20D) 4,533,595
Open 0.98
Previous Close 0.96
Day's Range 0.94 - 1.00
52-Week Range 0.93 - 3.94
Beta 0.86

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration a...

Sector Healthcare
IPO Date Jun 26, 2013
Employees 304
Stock Exchange NASDAQ
Ticker Symbol ESPR
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 322.12% from the latest price.

Stock Forecasts
1 month ago
+12.03%
Esperion Therapeutics shares are trading higher af... Unlock content with Pro Subscription
4 months ago
+5.58%
Esperion Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $8.